MDx/CDx Focus: MDxHealth Gains Access to Japanese CDx Market; UF Awarded NHGRI Grant | GenomeWeb

MDxHealth Gains Access to Japanese Pharmas Interested in Personalized Rx Development

MDxHealth has signed a deal with Summit Pharmaceuticals that will enable the molecular diagnostics firm to work with Japanese drug makers interested in advancing personalized treatments with companion tests.

Summit is a subsidiary of Sumitomo Corporation, which has 140 locations in 66 countries. Summit provides drug discovery research and production services in Japan.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.